More bad news this week. Zachs Research reports negative results for upcoming quarterly report May 9


anonymous

Guest
Just when you thought the bad news would go away for a few weeks it was reported by Zachs that Esperion has negative earnings report. The market responded today with the stock going down as low as $1.12. It finally stumbled up to $1.20. This isn't good as it will be a disaster as usual with more Covid excuses and talk of upticks and the addition of the Currax team who have no experience selling in this space. Do you think will end up under $1.00 a share?
 


Do you know the old saying, it’s always darkest before the dawn. We’ve really had our hands full from the get-go with Covid preventing a launch of any sort. Now here we are with outcomes data, which is great. No question. We’ve got our work cut out for us but it seems like folks are up for the challenge. There is a vast untapped market place that we can grab a small share of and be quite successful. It seems like momentum is on our side, and having some extra hands to help Will be a positive This is truly a value stock at this point. Long-term investors may be richly rewarded..
 


Are these valued investors the same ones who owned the stock when it was 78.00 a share 3 years ago. And do tou think Esperion was the only company that launched during Covid? I say bullshit as there were launches in 2020 that did 100's of millions while Esperion did 3 million a quarter a best. And love how you use Esperions favorite word... MOMENTUM!! The same momentum that puts us in the current state. The market and the medical community had already responded to The Notso Clear Data. Esperion is currently in litigation as there partner DS doesn't agree that Esperion should get a 300 million milestone award for not hitting the risk reduction that was contracted.
 


Do you know the old saying, it’s always darkest before the dawn. We’ve really had our hands full from the get-go with Covid preventing a launch of any sort. Now here we are with outcomes data, which is great. No question. We’ve got our work cut out for us but it seems like folks are up for the challenge. There is a vast untapped market place that we can grab a small share of and be quite successful. It seems like momentum is on our side, and having some extra hands to help Will be a positive This is truly a value stock at this point. Long-term investors may be richly rewarded..

Same old COVID excuse.

Now we are back to key words " Momentum " and " Value ".

Good golly.

Stop recycling the same old.
 






Just when you thought the bad news would go away for a few weeks it was reported by Zachs that Esperion has negative earnings report. The market responded today with the stock going down as low as $1.12. It finally stumbled up to $1.20. This isn't good as it will be a disaster as usual with more Covid excuses and talk of upticks and the addition of the Currax team who have no experience selling in this space. Do you think will end up under $1.00 a share?

You will know things are really unraveling if they:
-Roll out marketing research to show how excited physicians are about CLEAR outcomes and or
-They talk about managed care "wins"
 





Write your reply...